Inactive Instrument

Luye Pharma Group Ltd Stock Singapore S.E.

Equities

LUYE

BMG5722Z1014

Pharmaceuticals

Financials

Sales 2024 * 6.83B 941M 1.26B Sales 2025 * 7.81B 1.08B 1.44B Capitalization 10B 1.38B 1.85B
Net income 2024 * 677M 93.28M 125M Net income 2025 * 965M 133M 178M EV / Sales 2024 * 1.84 x
Net Debt 2024 * 2.59B 357M 479M Net Debt 2025 * 2.41B 332M 446M EV / Sales 2025 * 1.59 x
P/E ratio 2024 *
15.6 x
P/E ratio 2025 *
11.7 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.84%
More Fundamentals * Assessed data
Dynamic Chart
Chinese Regulator Approves Luye Pharma Group's New Drug for Marketing MT
Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China CI
Luye Pharma Group Ltd. Announces Manufacturing Facility of Paliperidone Palmitate Extended-Release Injectable Suspension Passed Pai by U.S. FDA with No FDA-483 CI
Luye Pharma Secures Chinese Medical Regulatory Approval for Parkinson’s Disease Treatment MT
Luye Pharma Group Ltd. Announces Its Jinyouping ® (Rotigotine Microspheres for Injection, Ly03003) Developed by the Group Has Been Approved CI
China Grants Marketing Approval to Luye Pharma's Anti-Schizophrenia Tablets MT
Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China CI
Luye Pharma's Japanese Partner Towa Files New Drug Application for Dementia Patch MT
Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao CI
Luye Enrolls First Patient into Phase III Trial of Anti-Cancer Drug MT
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610 CI
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3% MT
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States CI
Luye Pharma Says Two Medications Added to China's National Reimbursement Drug List MT
More news
Managers TitleAgeSince
Chief Executive Officer 59 03-07-01
President 58 94-06-07
Corporate Officer/Principal 60 94-06-07
Members of the board TitleAgeSince
Director/Board Member 65 94-06-07
President 58 94-06-07
Chief Executive Officer 59 03-07-01
More insiders
Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and Metabolism Drugs segment and the Others segment. The Company’s main products include paclitaxe for chemotherapy treatment of cancer, sodium glycididazole for radiotherapy for solid tumours, Chinese medicine for treatment of hypercholesterolaemia, and Rivastigmine Transdermal Patches for treatment of Alzheimer’s disease and dementia, among others. The products are sold under the name of Lipusu, CMNa, Xuezhikang, Maitongna ,and Bei X. Through its subsidiaries, the Company is also engaged in the provision of contract research and process development. The Company operates its business mainly in Mainland China.
More about the company